Profile
Hans Louis Jos de Winter was the founder and had founded Silicos SA in 2005, where he held the title of Director & CTO from 2010 to 2012.
He has worked as a Professor at Victoria University and as a Senior Scientist at The Janssen Research Foundation.
Dr. de Winter received his undergraduate degree in 1986 and his doctorate in 1992 from Université Catholique de Louvain.
Former positions of Hans Louis Jos de Winter
| Companies | Position | End |
|---|---|---|
Silicos SA
 Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Founder | 2012-05-10 |
| Victoria University | Corporate Officer/Principal | - |
| The Janssen Research Foundation | Chief Tech/Sci/R&D Officer | - |
Training of Hans Louis Jos de Winter
| Université Catholique de Louvain | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
| The Janssen Research Foundation |
- Stock Market
- Insiders
- Hans Louis Jos de Winter
